Anavex Life Sciences Corp (AVXL)

[sokol]

Yes, screening and selecting the patients for the AD trial is critical. However, over 20% of the 450 patients — around 100 patients — have been enrolled. Remember too that the PDD trial is a dementia trial. 70% enrollment in the PDD trial is achieved. If we receive positive news from the PDD trial, we should be attracting partners for Alzheimer’s and Parkinson's.
If we receive negative dementia results in the PDD trial, that will be a set back indeed, but I suppose it is possible that Anavex may still redeem itself with the larger number and more carefully selected patients in the AD trial.